A Phase 2 interventional study of MVA Smallpox vaccine and Placebo in Smallpox, sponsored by Sanofi Pasteur, a Sanofi Company. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-22.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing MVA-BN smallpox vaccine in Smallpox — none open to participants now, none under way, none of them phase 3. MVA-BN smallpox vaccine · Smallpox.
Among the 16 studies testing MVA-BN smallpox vaccine in Smallpox, this one is the 4th largest by enrollment, is one of 2 that started in 2005, is one of 10 in phase 2, and was the 8th registered.
73 studies on the registry are indexed under Smallpox; 5 are open to participants now.
Browse Smallpox studies →None of the 16 studies testing MVA-BN smallpox vaccine in Smallpox is open now. The open studies under Smallpox, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2 Smallpox studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 1
First in 2001; this study’s year is marked. 2 started in 2005.
This study's enrollment of 590 is above the median of 150 across 61 interventional studies indexed under Smallpox.
Median enrollment 196 across the 16 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 16 have an industry lead sponsor. The 3 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 7 studies filed under Smallpox — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing MVA-BN smallpox vaccine in Smallpox, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A phase 2 study to assess the MVA smallpox vaccine in previously vaccinated and vaccine- naive subjects at three dose levels.
This study will be a randomized, double-blind, placebo-controlled out-patient study conducted in multiple centers in the United States (US). Up to 700 healthy male and female adult subjects 18 to 55 years of age (inclusive), who have been previously vaccinated or subjects who are naïve to smallpox vaccine will be enrolled. Subjects will be randomized to 1 of 8 treatment groups with 100 (or 50 placebo) subjects per group in which they will receive either ACAM3000 MVA Smallpox Vaccine (1 of 3 dose levels) or placebo on Study Days 0 and 28. All personnel associated with the trial will be blinded as to treatment, with the exception of the study pharmacist who prepares the treatment for administration to each subject. There are 2 control groups in this study. A comparison of adverse events and other safety assessments between placebo and ACAM3000 MVA Smallpox Vaccine will be performed. In addition to serving as a control for safety, the previously vaccinated subjects receiving placebo will serve as a control for antibody and T-cell responses in persons with preexisting immunity who receive ACAM3000 MVA Smallpox Vaccine. Safety, tolerability, and immunogenicity data for 110 subjects undergoing primary immunization with graded doses of ACAM3000 MVA Smallpox Vaccine will be available following completion of Acambis protocol H-249-001, an ongoing phase I clinical trial. The doses levels in this study may be changed following the availability of results from protocol H-249-001. Statistical analysis will focus on comparisons among the dose levels of ACAM3000 MVA Smallpox Vaccine and comparisons of ACAM3000 MVA Smallpox Vaccine to placebo, as appropriate. A separate analysis will be performed for previously vaccinated and naïve subjects. Descriptive statistics will be used to compare demographic and baseline clinical data between stratum.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Previously vaccinated for smallpox, 1x10-8 dose
Drug: MVA Smallpox vaccine
Smallpox vaccine naive, 1x10-8 dose
Drug: MVA Smallpox vaccine
Previous smallpox vaccination, 1x10-7 dose
Drug: MVA Smallpox vaccine
Smallpox vaccine naive, 1x10-7 dose
Drug: MVA Smallpox vaccine
Previous smallpox vaccination, 1x10-6 dose
Drug: MVA Smallpox vaccine
Smallpox vaccine naive, 1x10-6 dose
Drug: MVA Smallpox vaccine
Previous smallpox vaccination, placebo dose
Drug: Placebo
Smallpox vaccine naive, placebo dose
Drug: Placebo
Two 0.5mL subcutaneous injections, separated by 28 days
Two 0.5mL subcutaneous injections, separated by 28 days
Safety
Time frame: Study Completion
Immunogenicity
Time frame: Study Completion
No study locations are listed for this record.
The record gives a start of Jul 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MVA-BN smallpox vaccine
Sanofi Pasteur, a Sanofi Company →